Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 1053-1058

  Dietrich, S ^a,b   Boumendil, A ^b   Finel, H ^b   Avivi, I ^b,c   Volin, L ^d   Cornelissen, J ^e   Jarosinska, R J ^f   Schmid, C ^g   Finke, J ^h   Stevens, W B C ⁱ   Schouten, H C ^b,j   Kaufmann, M ^k   Sebban, C ^l   Trneny, M ^b,m   Kobbe, G ⁿ   Fornecker, L M ^o   Schetelig, J ^p   Kanfer, E ^q   Heinicke, T ^r   Pfreundschuh, M ^s   Diez Martin, J L ^t   Bordessoule, D ^u   Robinson, S ^b,v   Dreger, P ^a,b   more..

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b EBMT Lymphoma Working Party   (France)

^c RAMBAM MEDICAL CENTER   (Israel)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g KLINIKUM AUGSBURG   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k ROBERT BOSCH HOSPITAL   (Germany)

^l CENTRE LÉON BÉRARD   (France)

^m INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

ⁿ HEINRICH HEINE UNIVERSITY   (Germany)

^o HÔPITAL DE HAUTEPIERRE   (France)

^p DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^q HAMMERSMITH HOSPITAL   (United Kingdom)

^r OTTO VON GUERICKE UNIVERSITY   (Germany)

^s SAARLAND UNIVERSITY   (Germany)

^t HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^u LIMOGES UNIVERSITY HOSPITAL   (France)

^v BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

more..

Author keywords

allogeneic stem cell transplantation; autologous stem cell transplantation; mantle cell lymphoma relapse

Indexed keywords

ADULT; AGED; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84920620829     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu097     Document Type: Article

References (16)

1. Herrmann, A., Hoster, E., Zwingers, T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27 (2009), 511–518.
2. Geisler, C.H., Kolstad, A., Laurell, A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112 (2008), 2687–2693.
3. Lefrere, F., Delmer, A., Suzan, F., et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 16 (2002), 587–593.
4. Dietrich, S., Tielesch, B., Rieger, M., et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 117 (2011), 1901–1910.
5. Hess, G., Herbrecht, R., Romaguera, J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27 (2009), 3822–3829.
6. Fisher, R.I., Bernstein, S.H., Kahl, B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24 (2006), 4867–4874.
7. Wang, M.L., Rule, S., Martin, P., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369 (2013), 507–516.
8. Robinson, S.P., Goldstone, A.H., Mackinnon, S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002), 4310–4316.
9. Cook, G., Smith, G.M., Kirkland, K., et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16 (2010), 1419–1427.
10. Tam, C.S., Bassett, R., Ledesma, C., et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113 (2009), 4144–4152.
11. Hermine, O., Hoster, E., Walewski, J., et al. Alternating courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)., 2012 oral presentation ASH Atlanta.
12. Maris, M.B., Sandmaier, B.M., Storer, B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004), 3535–3542.
13. Khouri, I.F., Lee, M.S., Saliba, R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21 (2003), 4407–4412.
14. Le Gouill, S., Kroger, N., Dhedin, N., et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23 (2012), 2695–2703.
15. Brett, L.K., Williams, M.E., Current and emerging therapies in mantle cell lymphoma. Curr Treat Opt Oncol 14 (2013), 198–211.
16. Hamadani, M., Saber, W., Ahn, K.W., et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 19 (2013), 625–631.